Benzinga
Benzinga
Benzinga
domenica, settembre 20

Abbott Laboratories

ABTNYSE
Trade with Public
Trade with Public
$102.61
0.380.37%
In chiusura: Sep 18, 5:00 PM EST
$102.61
N/A
Post-mercato: Sep 18, 4:13 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

Abbott Laboratories Financials

Abbott Laboratories (ABT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Abbott Laboratories (NYSE:ABT) reported strong Q2 results, raising its full-year earnings outlook. Analysts have a positive outlook on ABT stock.
Avi Kapoor

Why Is Intuitive Surgical Stock Sinking Friday?

ISRG stock drops 11% as Intuitive Surgical beats Q2 estimates but warns insurance changes could slow U.S. procedure growth.
Lekha Gupta

Nasdaq Tumbles 1.5% Amid Selloff In Chip Stocks: Investor Sentiment Weakens, Greed Index Moves To ‘Fear’ Zone

Market sentiment declined as stocks fell, with tech stocks leading the way. UnitedHealth Group and Abbott Laboratories reported strong earnings.
Avi Kapoor

Abbott Brushes Off Procedure Volume Concerns, Lifts Outlook

Abbott (ABT) stock jumps 12% after beating Q2 2026 earnings and revenue estimates and raising its full-year profit outlook. Read more.
Vandana Singh

PRO
Abbott Projects Full-Year 2026 Comparable Sales Growth Of 6.5% To 7.5%

Benzinga Newsdesk

PRO
Abbott Laboratories Sees Q3 Adj EPS $1.38-$1.46 vs $1.42 Est

Abbott Laboratories (NYSE:ABT) is looking for Q3 Adj EPS of $1.38-$1.46 vs $1.42 analyst estimate..
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved